Abstract
Evaluation of the effectiveness of bone metastasis therapy is an urgent problem for patients with prostate cancer, mainly due to the relationship between bone metastases, survival and quality of life, which directly depends on the correct interpretation of the results of treatment response. It is known that some patients may experience a multidirectional therapeutic effect in the form of a positive response of some bone metastases and the progression of others. In addition, there are now many new therapeutics with different action profiles and often extremely expensive, so it is important to quickly recognize whether true or pseudo-disease progression is occurring, and this is more evident in patients enrolled in clinical trials with fixed protocols, often requiring radiographic assessment early after the start of treatment. Therefore, the use of additional imaging modalities in clinical practice along with PSA assessment may help improve early prediction of outcome and monitor response to therapy in patients with metastatic CRPC, optimizing the use of this costly treatment.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
